Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
133 EUR | -2.73% | -1.98% | -3.40% |
08:02pm | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
07:43pm | Sector Update: Health Care | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's enterprise value to sales, at 3.92 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.40% | 354B | - | ||
+37.44% | 727B | C+ | ||
+15.45% | 328B | B- | ||
-0.53% | 277B | C+ | ||
+13.47% | 243B | B+ | ||
+7.35% | 205B | B- | ||
-6.42% | 203B | A+ | ||
+3.63% | 164B | C+ | ||
-2.08% | 164B | C+ | ||
-1.31% | 122B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson